GlassScriptPhysician profile
Emem Dan Udonta
NPI 1851377675
$30,537.12
in general payments reported to CMS, 2019-2025
66 companies · $4,027 in 2025
The $4,027 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,639 · 2020: $2,661 · 2021: $2,514 · 2022: $8,411 · 2023: $7,119 · 2024: $3,167 · 2025: $4,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,862 · Honoraria: $2,584 · Travel and Lodging: $1,209 · Education: $507 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,862.38 |
| Honoraria | $2,583.75 |
| Travel and Lodging | $1,209.32 |
| Education | $506.52 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $5,642.75 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biocodex, INC. | $3,919.00 | 2023 | Diacomit |
| Acadia Pharmaceuticals INC | $1,958.97 | 2019-2025 | Nuplazid |
| Biogen, INC. | $1,490.25 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Abbvie INC. | $1,302.63 | 2019-2025 | Qulipta, Duopa, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,283.59 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,088.20 | 2019-2025 | |
| Emd Serono, INC. | $883.90 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $880.90 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Lundbeck LLC | $864.33 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $633.70 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $526.75 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $507.68 | 2019-2025 | Rytary, Crexont |
| Sunovion Pharmaceuticals INC. | $497.14 | 2019-2022 | |
| Harmony Biosciences LLC | $486.42 | 2020-2025 | Wakix |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $471.31 | 2020-2025 | Xcopri |
| Kyowa Kirin, INC. | $427.86 | 2020-2024 | Nourianz |
| Supernus Pharmaceuticals, INC. | $389.73 | 2019-2024 | Qelbree, Oxtellar Xr |
| Jazz Pharmaceuticals INC. | $355.85 | 2022-2025 | Epidiolex, Xywav |
| Acorda Therapeutics, INC | $348.51 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $346.47 | 2019-2025 | Ultomiris |
| Mdd US Operations, LLC | $342.25 | 2019-2024 | Apokyn |
| Neurelis, INC. | $333.76 | 2020-2024 | Valtoco |
| Grifols USA, LLC | $319.68 | 2019-2025 | Gamunex-C |
| Celgene Corporation | $311.45 | 2020-2025 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $304.73 | 2023-2025 | Nuedexta, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $299.34 | 2023-2025 | Hyqvia, Gammagard |
| Lilly USA, LLC | $288.11 | 2019-2025 | Kisunla, Amyvid |
| Csl Behring | $254.49 | 2019-2025 | Hizentra |
| Genzyme Corporation | $219.69 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $212.78 | 2021 | |
| Boston Scientific Corporation | $211.31 | 2021-2023 | Vercise |
| Merz Pharmaceuticals, LLC | $183.75 | 2021-2024 | Xeomin |
| Janssen Biotech, INC. | $181.56 | 2025 | |
| Neuropace, INC. | $173.94 | 2024 | |
| Allergan, INC. | $167.86 | 2019-2021 | |
| Insightec,INC | $164.22 | 2024 | Exablate |
| Pfizer INC. | $159.41 | 2023-2025 | |
| Livanova USA, INC. | $148.70 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $129.62 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $126.10 | 2024-2025 | Acthar |
| Medtronic USA, INC. | $126.08 | 2019 | |
| Tg Therapeutics, INC. | $124.86 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $112.02 | 2019-2022 | |
| Amgen INC. | $110.01 | 2019-2025 | Uplizna |
| Arbor Pharmaceuticals, INC. | $101.86 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $94.88 | 2020-2023 | |
| Avion Pharmaceuticals | $92.99 | 2022 | |
| Banner Life Sciences, LLC | $90.85 | 2021-2022 | |
| Ge Healthcare | $90.43 | 2019-2023 | |
| Corium, LLC | $86.42 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $77.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $75.26 | 2021-2022 | |
| Abbott Laboratories | $68.26 | 2019-2025 | Infinity |
| E.R. Squibb & Sons, L.L.C. | $67.42 | 2020-2022 | |
| Genentech USA, INC. | $58.18 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $47.01 | 2023 | Aptiom |
| Impel Pharmaceuticals LLC | $39.90 | 2024-2025 | Trudhesa |
| Assertio Therapeutics, INC. | $39.59 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $36.87 | 2021 | |
| Inspire Medical Systems, INC. | $34.25 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $29.78 | 2025 | Symbravo |
| Almatica Pharma LLC | $29.17 | 2021 | |
| Currax Pharmaceuticals LLC | $28.80 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $23.81 | 2025 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emem Udonta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.